Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <scp>MASK</scp> study

  • J. Bousquet
    MACVIA‐France Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site Montpellier France
  • P. Devillier
    Laboratoire de Pharmacologie Respiratoire UPRES EA220 Pôle des Maladies Respiratoires Hôpital Foch Suresnes Université Versailles Saint‐Quentin Suresnes France
  • J. M. Anto
    ISGloBAL Centre for Research in Environmental Epidemiology (CREAL) Barcelona Spain
  • M. Bewick
    iQ4U Consultants Ltd London UK
  • T. Haahtela
    Skin and Allergy Hospital Helsinki University Hospital Helsinki Finland
  • S. Arnavielhe
    Kyomed Montpellier France
  • A. Bedbrook
    MACVIA‐France Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site Montpellier France
  • R. Murray
    MedScript Ltd Dundalk Ireland
  • M. van Eerd
    Peercode DV Gerdermalsen The Netherlands
  • J. A. Fonseca
    Faculdade de Medicina Center for Health Technology and Services Research‐ CINTESIS MEDIDA, Lda Universidade do Porto Porto Portugal
  • M. Morais Almeida
    Allergy and Clinical Immunology Department Hospital CUF‐Descobertas Lisboa Portugal
  • A. Todo Bom
    Imunoalergologia Faculty of Medicine Centro Hospitalar Universitário de Coimbra University of Coimbra Coimbra Portugal
  • E. Menditto
    CIRFF Center of Pharmacoeconomics University of Naples Federico II Naples Italy
  • G. Passalacqua
    Allergy and Respiratory Diseases Ospedale Policlinico San Martino University of Genoa Genoa Italy
  • C. Stellato
    Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana” University of Salerno Salerno Italy
  • M. Triggiani
    Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana” University of Salerno Salerno Italy
  • M. T. Ventura
    Unit of Geriatric Immunoallergology University of Bari Medical School Bari Italy
  • G. Vezzani
    Pulmonary Unit Department of Medical Specialties Arcispedale SMaria Nuova/IRCCS AUSL di Reggio Emilia Reggio Emilia Italy
  • I. Annesi‐Maesano
    Epidemiology of Allergic and Respiratory Diseases Department Institute Pierre Louis of Epidemiology and Public Health INSERM Medical School Saint Antoine UPMC Sorbonne Universités Paris France
  • R. Bourret
    Centre Hospitalier Valenciennes France
  • I. Bosse
    Allergist La Rochelle France
  • D. Caimmi
    CHRU de Montpellier UMR‐S 1136 IPLESP Equipe EPAR UPMC Paris 06 Sorbonne Universités Paris France
  • C. Cartier
    ASA ‐ Advanced Solutions Accelerator Clapiers France
  • P. Demoly
    CHRU de Montpellier UMR‐S 1136 IPLESP Equipe EPAR UPMC Paris 06 Sorbonne Universités Paris France
  • J. Just
    Allergology Department Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand‐Trousseau (APHP) Paris France
  • F. Portejoie
    MACVIA‐France Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site Montpellier France
  • V. Siroux
    INSERM IAB, U 1209 Team of Environmental Epidemiology applied to Reproduction and Respiratory Health Université Grenoble Alpes Université Joseph Fourier Grenoble France
  • F. Viart
    ASA ‐ Advanced Solutions Accelerator Clapiers France
  • K. C. Bergmann
    Department of Dermatology and Allergy Comprehensive Allergy‐Centre‐Charité Charité ‐ Universitätsmedizin Berlin Berlin Germany
  • T. Keil
    Institute of Social Medicine, Epidemiology and Health Economics Charité ‐ Universitätsmedizin Berlin Berlin Germany
  • L. Klimek
    Center for Rhinology and Allergology Wiesbaden Germany
  • R. Mösges
    CRI‐Clinical Research International‐Ltd Hamburg Germany
  • O. Pfaar
    Center for Rhinology and Allergology Wiesbaden Germany
  • S. Shamai
    CRI‐Clinical Research International‐Ltd Hamburg Germany
  • T. Zuberbier
    Department of Dermatology and Allergy Comprehensive Allergy‐Centre‐Charité Charité ‐ Universitätsmedizin Berlin Berlin Germany
  • J. Mullol
    Rhinology Unit & Smell Clínic ENT Department Hospital Clinic University of Barcelona Barcelona Spain
  • A. Valero
    Rhinology Unit & Smell Clínic ENT Department Hospital Clinic University of Barcelona Barcelona Spain
  • O. Spranger
    Global Allergy and Asthma Platform GAAPP Vienna Austria
  • P. V. Tomazic
    Department of ENT Medical University of Graz Graz Austria
  • M. L. Kowalski
    Department of Immunology, Rheumatology and Allergy HARC Medical University of Lodz Lodz Poland
  • P. Kuna
    Division of Internal Medicine, Asthma and Allergy Barlicki University Hospital Medical University of Lodz Lodz Poland
  • M. Kupczyk
    Division of Internal Medicine, Asthma and Allergy Barlicki University Hospital Medical University of Lodz Lodz Poland
  • F. Raciborski
    Department of Prevention of Envinronmental Hazards and Allergology Medical University of Warsaw Warsaw Poland
  • B. Samolinski
    Department of Prevention of Envinronmental Hazards and Allergology Medical University of Warsaw Warsaw Poland
  • S. K. Toppila‐Salmi
    Skin and Allergy Hospital Helsinki University Hospital Helsinki Finland
  • E. Valovirta
    Department of Lung Diseases and Clinical Immunology University of Turku Turku Finland
  • A. A. Cruz
    ProAR – Nucleo de Excelencia em Asma Federal University of Bahia Salvador Brasil
  • F. Sarquis‐Serpa
    Asthma Reference Center Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria Esperito Santo Brazil
  • J. da Silva
    Nucleo de Alergia Hospital Universitario Polydoro Ernani de Sao Thiago Federal University of Santa Catarina (HU‐UFSC) Florioanopolis Brazil
  • R. Stelmach
    Pulmonary Division Heart Institute (InCor) Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo Sao Paulo Brazil
  • D. Larenas‐Linnemann
    Center of Excellence in Asthma and Allergy Hospital Médica Sur México City Mexico
  • M. Rodriguez Gonzalez
    Pediatric Allergy and Clinical Immunology Hospital Angeles Pedregal Mexico City Mexico
  • M. T. Burguete Cabañas
    Centro Médico Zambrano Hellion Monterrey Mexico
  • V. Kvedariene
    Departement of Pathology, Forensic Medicine and Pharmacology Faculty of Medicine Clinic of Infecious, Chest Diseases, Dermatology and Allergology Institute of Biomedical Sciences Vilnius University Vilnius Lithuania
  • A. Valiulis
    Department of Public Health Clinic of Children's Diseases Institute of Health Sciences Vilnius University Institute of Clinical Medicine Vilnius Lithuania
  • N. H. Chavannes
    Department of Public Health and Primary Care Leiden University Medical Center Leiden The Netherlands
  • W. J. Fokkens
    Department of Otorhinolaryngology Academic Medical Centre Amsterdam The Netherlands
  • D. Ryan
    Allergy and Respiratory Research Group Usher Institute of Population Health Sciences and Informatics University of Edinburgh Edinburgh UK
  • A. Sheikh
    Asthma UK Centre for Applied Research Centre of Medical Informatics Usher Institute of Population Health Sciences and Informatics The University of Edinburgh Edinburgh UK
  • C. Bachert
    ENT Department Upper Airways Research Laboratory Ghent University Hospital Ghent Belgium
  • P. W. Hellings
    Euforea Brussels Belgium
  • O. VandenPlas
    Department of Chest Medicine Centre Hospitalier Universitaire UCL Namur Université Catholique de Louvain Yvoir Belgium
  • N. Ballardini
    Centre for Clinical Research Sörmland Uppsala University Eskilstuna Sweden
  • I. Kull
    Allergy and Respiratory Research Group Usher Institute of Population Health Sciences and Informatics University of Edinburgh Edinburgh UK
  • E. Melén
    Sachs’ Children and Youth Hospital Södersjukhuset Stockholm Sweden
  • M. Westman
    Department of Medicine Solna Immunology and Allergy Unit Karolinska Institutet Stockholm Sweden
  • M. Wickman
    Centre for Clinical Research Sörmland Uppsala University Eskilstuna Sweden
  • C. Bindslev‐Jensen
    Department of Dermatology and Allergy Centre Odense Research Center for Anaphylaxis (ORCA) Odense University Hospital Odense Denmark
  • E. Eller
    Department of Dermatology and Allergy Centre Odense Research Center for Anaphylaxis (ORCA) Odense University Hospital Odense Denmark
  • S. Bosnic‐Anticevich
    Woolcock Institute of Medical Research Sydney Local Health District University of Sydney Glebe NSW Australia
  • R. E. O'Hehir
    Department of Allergy, Immunology and Respiratory Medicine Alfred Hospital and Central Clinical School Monash University Melbourne Vic. Australia
  • I. Agache
    Transylvania University Brasov Romania
  • T. Bieber
    Department of Dermatology and Allergy Rheinische Friedrich‐Wilhelms‐University Bonn Bonn Germany
  • T. Casale
    Division of Allergy/Immunology University of South Florida Tampa FL USA
  • B. Gemicioğlu
    Department of Pulmonary Diseases Cerrahpasa Faculty of Medicine Istanbul University Istanbul Turkey
  • J. C. Ivancevich
    Servicio de Alergia e Immunologia Clinica Santa Isabel Buenos Aires Argentina
  • G. De Vries
    Peercode DV Gerdermalsen The Netherlands
  • M. Sorensen
    Department of Paediatric and Adolescent Medicine University Hospital of North Norway Tromsø Norway
  • A. Yorgancioglu
    Department of Pulmonology Celal Bayar University Manisa Turkey
  • D. Laune
    Kyomed Montpellier France

抄録

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Multimorbidity in allergic airway diseases is well known, but no data exist about the daily dynamics of symptoms and their impact on work. To better understand this, we aimed to assess the presence and control of daily allergic multimorbidity (asthma, conjunctivitis, rhinitis) and its impact on work productivity using a mobile technology, the <jats:italic>Allergy Diary</jats:italic>.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We undertook a 1‐year prospective observational study in which 4 210 users and 32 585 days were monitored in 19 countries. Five visual analogue scales (VAS) assessed the daily burden of the disease (i.e., global evaluation, nose, eyes, asthma and work). Visual analogue scale levels <20/100 were categorized as “Low” burden and VAS levels ≥50/100 as “High” burden.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Visual analogue scales global measured levels assessing the global control of the allergic disease were significantly associated with allergic multimorbidity. Eight hypothesis‐driven patterns were defined based on “Low” and “High” VAS levels. There were <0.2% days of Rhinitis Low and Asthma High or Conjunctivitis High patterns. There were 5.9% days with a Rhinitis High—Asthma Low pattern. There were 1.7% days with a Rhinitis High—Asthma High—Conjunctivitis Low pattern. A novel Rhinitis High—Asthma High—Conjunctivitis High pattern was identified in 2.9% days and had the greatest impact on uncontrolled VAS global measured and impaired work productivity. Work productivity was significantly correlated with VAS global measured levels.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In a novel approach examining daily symptoms with mobile technology, we found considerable intra‐individual variability of allergic multimorbidity including a previously unrecognized extreme pattern of uncontrolled multimorbidity.</jats:p></jats:sec>

収録刊行物

  • Allergy

    Allergy 73 (8), 1622-1631, 2018-04-24

    Wiley

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ